-
Phase 3
-
-
15+Age Range
-
Active, Not Recruiting
Menu
Thank you for submitting your question. You will get a reply within two business days to the email you provided. Thank you.
Active, Not Recruiting
Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
Inclusion Criteria: - At least 15 years of age Except: where local regulations and/or institutional policies do not allow for subjects < 18 years of age (pediatric population) to participate. For those sites, the eligible subject population is ≥ 18 years of age - Completely removed melanoma by surgery performed within 12 weeks of randomization - Stage IIIb/C or Stage IV before complete resection - No previous anti-cancer treatment Exclusion Criteria: - Ocular or uveal melanoma - History of carcinomatosis meningitis - History of auto-immune disease - Treatment directed against the resected melanoma that is administrated after the surgery Other protocol-defined inclusion/exclusion criteria apply
Study Arms
Experimental: Ipilimumab and Placebo matching Nivolumab
Study Arms
Experimental: Nivolumab and Placebo matching Ipilimumab